Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or in combination with other therapies to improve glycemic control in patients with T2DM. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of treatment for T2DM that reduce hyperglycemia by reducing renal glucose reabsorption and thereby increasing urinary glucose excretion. This paper reviews the pharmacokinetic and pharmacodynamic properties of the SGLT2 inhibitor empagliflozin , the results of clinical trials investigating the efficacy of empagliflozin given as monotherapy or as add-on therapy on glycemic control, body weight, and blood pressure in patients with T2DM, and the safety and tolerability profile of empagliflozin. Empagliflozin offers good glycemic efficacy, weight loss, blood pressure reduction, and a low risk of hypoglycemia. These attributes, coupled with the ability to be used in virtually any combination with other anti-diabetes agents and at any stage in the disease process, provide a welcome new agent to our armamentarium of drugs to help manage T2DM.
Despite the availability of numerous anti - diabetes drugs and treatment guidelines , many patients with type 2 diabetes mellitus ( T2DM ) do not reach recommended targets for glycemic control . There remains an unmet need for effective and well - tolerated anti - diabetes agents that can be used as monotherapy or in combination with other therapies to improve glycemic control in patients with T2DM . Sodium glucose cotransporter 2 ( SGLT2 ) inhibitors are a new class of treatment for T2DM that reduce hyperglycemia by reducing renal glucose reabsorption and thereby increasing urinary glucose excretion . This paper reviews the pharmacokinetic and pharmacodynamic properties of the SGLT2 inhibitor empagliflozin , the results of clinical trials investigating the efficacy of empagliflozin given as monotherapy or as add - on therapy on glycemic control , body weight , and blood pressure in patients with T2DM , and the safety and tolerability profile of empagliflozin . Empagliflozin offers good glycemic efficacy , weight loss , blood pressure reduction , and a low risk of hypoglycemia . These attributes , coupled with the ability to be used in virtually any combination with other anti - diabetes agents and at any stage in the disease process , provide a welcome new agent to our armamentarium of drugs to help manage T2DM .
Which protein does empagliflozin inhibit?
Which protein does empagliflozin inhibit ?
SGLT2
SGLT2